Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

February 2022 | 112 pages | ID: T597A2F93F49EN
Global Markets Direct

Abstracts

Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation, and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 41 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 10, 1, 14 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Musculoskeletal Disorders, Ophthalmology, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Genetic Disorders, Infectious Disease, Cardiovascular, Central Nervous System, Dermatology, Hematological Disorders and Male Health which include indications Solid Tumor, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Non-Small Cell Lung Cancer, Colorectal Cancer, Kidney Fibrosis, Liver Fibrosis, Myelofibrosis, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Diabetic Nephropathy, Fibrosis, Liver Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Squamous Cell Carcinoma, Bladder Cancer, Corneal Dystrophy, Coronavirus Disease 2019 (COVID-19), Glioblastoma Multiforme (GBM), Melanoma, Metastatic Liver Cancer, Non-Alcoholic Steatohepatitis (NASH), Osteoarthritis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Sclerosing Cholangitis, Renal Cell Carcinoma, Systemic Sclerosis (Scleroderma), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Unspecified Cancer, Age Related Macular Degeneration, Alport Syndrome, Anemia, Basal Cell Carcinoma (Basal Cell Epithelioma), Benign Prostatic Hyperplasia, Bone Disorders, Cholangitis, Choroidal Neovascularization, Colitis, Colon Cancer, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Glaucoma, Gynecological Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hyperalgesia, Hypertrophic Scars, Inflammation, Interstitial Lung Fibrosis, Keloids, Lung Adenocarcinoma, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatitis Pain, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension and Transitional Cell Cancer (Urothelial Cell Cancer).

The latest report Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
• The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1) Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) - Overview
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AiViva BioPharma Inc, 2022
Pipeline by AskGene Pharma Inc, 2022
Pipeline by Avellino Lab USA Inc, 2022
Pipeline by Bonac Corp, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Certa Therapeutics Pty Ltd, 2022
Pipeline by Chengdu Huitai Biomedicine Co Ltd, 2022
Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Pipeline by Ensol Biosciences Inc, 2022
Pipeline by Genoscience Pharma, 2022
Pipeline by Genzyme Corp, 2022
Pipeline by Guangzhou Nanxin Pharmaceutical Co Ltd, 2022
Pipeline by HitGen Inc, 2022
Pipeline by Isarna Therapeutics GmbH, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Lepu Biopharma Co Ltd, 2022
Pipeline by Nanjing Shenghe Pharmaceutical Co Ltd, 2022
Pipeline by Novartis AG, 2022
Pipeline by Phio Pharmaceuticals Corp, 2022
Pipeline by Scholar Rock Inc, 2022
Pipeline by Sirnaomics Inc, 2022
Pipeline by Sisaf Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022